Company Overview of Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. discovers and develops novel antibody-based drugs targeting receptor tyrosine kinases (RTK) for the treatment of cancer and other diseases. Its lead product candidate includes KTN3379, an antibody targeting the ErbB3 RTK, which is in Phase I clinical trials for adult patients with advanced solid tumors. The company is also developing KTN0158, a KIT RTK inhibitor for the treatment of neurofibromatosis type 1 and other inflammatory diseases; and KIT-ADC, an antibody drug conjugate for oncology treatment, as well as a range of research programs targeting RTKs. Kolltan Pharmaceuticals, Inc. was founded in 2007 and is based in New Haven, Connecticut.
300 George Street
New Haven, CT 06511
Founded in 2007
Key Executives for Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Bio-Research Products, Inc.||United States|
|Neurotech Pharmaceuticals, Inc.||United States|
|BioProcessing, Inc.||United States|
|MakuCell, Inc.||United States|
|Matrix Genetics||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Kolltan Pharmaceuticals, Inc., please visit www.kolltan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.